An unprecedented vaccination strategy implemented in Wales has provided scientists with some of the most compelling evidence to date that a widely available vaccine could play a crucial role in protecting against dementia. A new study, spearheaded by researchers at Stanford Medicine, meticulously analyzed health records from hundreds of thousands of older adults across Wales. The findings, published on April 2 in the prestigious journal Nature, revealed a significant association: individuals who received the shingles vaccine were found to be 20% less likely to be diagnosed with dementia over a subsequent seven-year period compared to their unvaccinated counterparts. This discovery lends substantial weight to a burgeoning scientific hypothesis that certain neurotropic viruses, those capable of infecting the nervous system, may increase an individual’s susceptibility to developing dementia. Should these initial findings be consistently replicated in subsequent research, they suggest that a practical and accessible method for dementia prevention may already be within reach. Adding another layer to these significant insights, a second analysis conducted by the same research team, and published earlier on December 2 in Cell, indicated a further potential benefit. This follow-up study reported that the shingles vaccine might also offer a therapeutic advantage for individuals already living with dementia, by potentially slowing the rate at which the debilitating condition progresses. The Global Burden of Dementia and the Shifting Research Landscape Dementia represents one of the most pressing global health challenges of our time, currently affecting an estimated 55 million people worldwide. The toll continues to rise, with approximately 10 million new cases diagnosed annually, posing immense burdens on individuals, families, and healthcare systems. For decades, the vast majority of dementia research has concentrated on the accumulation of abnormal proteins within the brain, such as the amyloid plaques and tau tangles that are hallmark pathological features of Alzheimer’s disease, the most common form of dementia. Despite extensive efforts and substantial investment in this area, these research avenues have, to date, not yielded universally successful strategies for preventing, effectively treating, or halting the progression of the disease. This persistent lack of breakthroughs has prompted an increasing number of scientists to explore alternative potential drivers of dementia, including the intriguing possibility that infections by specific viruses could inflict cumulative damage on the brain over time, ultimately contributing to neurodegeneration. Understanding Shingles and the Varicella-Zoster Virus Shingles, medically known as herpes zoster, is a viral disease characterized by a painful, blistering skin rash that typically appears in a band or patch on one side of the body. The causative agent is the varicella-zoster virus (VZV), the very same pathogen responsible for chickenpox. When an individual contracts chickenpox, usually during childhood, the virus does not entirely clear from the body. Instead, it enters a dormant, inactive state, residing silently within nerve cells, specifically in the dorsal root ganglia, for the remainder of the person’s life. In later years, particularly in older adults or individuals with compromised immune systems due to illness, stress, or certain medications, this latent virus can reactivate. When VZV reactivates, it travels along the nerve pathways to the skin, causing the characteristic painful rash of shingles. Beyond the rash, shingles can lead to severe and long-lasting complications, including post-herpetic neuralgia (PHN), a persistent nerve pain that can linger for months or even years after the rash has cleared. The existence of effective vaccines against shingles, therefore, not only prevents the immediate discomfort of the disease but also mitigates the risk of such debilitating sequelae. The Welsh "Natural Experiment": A Methodological Breakthrough Earlier observational studies, which utilized health records from various populations, had previously offered tantalizing hints that individuals who received the shingles vaccine might exhibit a lower likelihood of developing dementia. However, these studies were plagued by a significant methodological limitation known as "healthy user bias." This bias arises because people who actively seek vaccination often possess a greater overall health consciousness. They may adhere to healthier diets, engage in more regular physical activity, and proactively seek healthcare, all of which are known factors that can independently influence dementia risk. These crucial lifestyle differences are typically not systematically recorded in medical databases, making it exceedingly difficult to disentangle the direct effect of the vaccine from these confounding variables. "All these associational studies suffer from the basic problem that people who go get vaccinated have different health behaviors than those who don’t," explained Pascal Geldsetzer, MD, PhD, an assistant professor of medicine at Stanford and the senior author of the new study. He added, "In general, they’re seen as not being solid enough evidence to make any recommendations on." Approximately two years ago, Dr. Geldsetzer and his team recognized an extraordinary opportunity presented by the specific rollout strategy of Wales’ national shingles vaccination program. This unique implementation functioned as what researchers term a "natural experiment," a quasi-experimental design that allowed them to circumvent many of the biases inherent in previous observational studies. At the time of this program, Wales utilized a version of the shingles vaccine that contained a live-attenuated, or weakened, form of the virus (Zostavax, since largely superseded by the recombinant protein vaccine, Shingrix, in many countries). The national program officially commenced on September 1, 2013. Under the established policy, any individual who was 79 years old on that precise date became eligible to receive the vaccine during the subsequent year. This rolling eligibility meant that those who turned 78 in the preceding year would become eligible the following year for a one-year window, and so on. Critically, individuals who were 80 years old or older on September 1, 2013, were explicitly excluded from eligibility; they would never qualify for the vaccine under this particular program. This precise age-based cut-off created a distinct and powerful analytical advantage. Eligibility for vaccination depended solely on an individual’s age relative to a specific calendar date, meaning that the minute difference of being just under or just over the age threshold had a profound impact on whether a person could receive the vaccine. This allowed the researchers to construct two nearly identical comparison groups: those who turned 80 just before September 1, 2013, and were therefore ineligible, versus those who turned 80 just after September 1, 2013, and were thus eligible. This design effectively minimized the influence of unmeasured lifestyle factors, as individuals born merely a week apart are unlikely to differ significantly in their health-seeking behaviors or other dementia risk factors. According to Dr. Geldsetzer, the exceptionally detailed and comprehensive health records available within the Welsh healthcare system further enhanced the robustness of these circumstances, making the study design as close as possible to a randomized controlled trial without actually conducting one. Robust Findings: A Dual Protective Effect Against Dementia To leverage this powerful natural experiment, Dr. Geldsetzer’s team meticulously analyzed the anonymized health records of more than 280,000 older adults, ranging in age from 71 to 88 years, all of whom were free of a dementia diagnosis at the inception of the vaccination program. The core of their analysis focused on individuals whose birthdays positioned them precisely on either side of the eligibility threshold, comparing those who turned 80 in the week immediately prior to September 1, 2013, with those who reached their 80th birthday in the week immediately following that date. "We know that if you take a thousand people at random born in one week and a thousand people at random, born a week later, there shouldn’t be anything different about them on average," Dr. Geldsetzer articulated. "They are similar to each other apart from this tiny difference in age." The researchers reasonably assumed that approximately the same proportion of individuals in both groups would have been inclined to receive the shingles shot. The crucial differentiator, however, was that only the slightly younger cohort—those not yet 80 on September 1, 2013—were legally permitted to receive the vaccine under the program’s strict rules. "What makes the study so powerful is that it’s essentially like a randomized trial with a control group – those a little bit too old to be eligible for the vaccine – and an intervention group – those just young enough to be eligible," Dr. Geldsetzer elaborated, highlighting the methodological strength. The team then meticulously tracked the health outcomes for these cohorts over a subsequent seven-year period, comparing individuals of similar ages who had been either eligible or ineligible for the vaccine. By cross-referencing this eligibility information with actual vaccination rates, they were able to estimate the real-world effect of receiving the shot. Notably, about half of the eligible individuals ultimately opted to be vaccinated, while virtually none of those deemed ineligible received it, underscoring the clear distinction created by the policy. As anticipated and consistent with previous clinical trial data, the live-attenuated vaccine significantly lowered the rate of shingles diagnoses over the seven-year follow-up period, demonstrating an approximate 37% reduction among those who were vaccinated. This effectiveness, however, is known to wane over time. By 2020, when the individuals under study were approximately 86 and 87 years old, a concerning one in eight had developed dementia. Crucially, among those who had received the shingles shot, the likelihood of a dementia diagnosis was a remarkable 20% lower when compared to their unvaccinated counterparts. "It was a really striking finding," Dr. Geldsetzer commented on the results. "This huge protective signal was there, any which way you looked at the data." Beyond Prevention: Slowing Progression in Existing Dementia The researchers extended their inquiry to investigate whether the observed benefits of the vaccine were confined solely to preventing the onset of dementia, or if they also offered advantages to individuals who already exhibited signs of cognitive impairment. Employing the same natural experiment framework, they examined a broader spectrum of outcomes, ranging from mild cognitive changes to advanced stages of dementia. Many cases of dementia are known to be preceded by a period classified as mild cognitive impairment (MCI), characterized by noticeable deficits in memory or other cognitive skills that, critically, do not yet interfere with an individual’s ability to live independently. The team observed that individuals who had received the shingles vaccine were significantly less likely to receive a diagnosis of mild cognitive impairment during a nine-year follow-up period than those who remained unvaccinated. Perhaps even more profoundly, the researchers also focused on a group of individuals who had already been diagnosed with dementia at the very start of the Welsh vaccination program in 2013. In this specific cohort, the results were particularly striking. Individuals with existing dementia who received the shingles shot were significantly less likely to die from dementia in the subsequent nine years, as indicated on their official death certificates, compared to those who did not receive the vaccine. This compelling finding strongly suggests that the progression of the disease may have been substantially slowed in the vaccinated group. In total, nearly half of the 7,049 Welsh seniors who had dementia when the program began ultimately died from dementia during the follow-up period. Among those with dementia who received the vaccine, however, only approximately 30% died from dementia, representing a substantial reduction in dementia-related mortality. "The most exciting part is that this really suggests the shingles vaccine doesn’t have only preventive, delaying benefits for dementia, but also therapeutic potential for those who already have dementia," Dr. Geldsetzer enthused, underscoring the potential for a groundbreaking shift in dementia management. Ruling Out Other Explanations and Unanswered Questions To ensure the robustness of their findings, the researchers undertook extensive efforts to search for any other factors that might plausibly explain the observed difference in dementia rates between the two groups. Their exhaustive analysis confirmed that the eligible and ineligible groups were remarkably similar across all measurable characteristics. Education levels were virtually identical for both groups. Furthermore, those who were eligible for the shingles vaccine were not found to be more likely to have received other vaccines or preventive therapies, nor were they less likely to suffer from common chronic illnesses such as diabetes, heart disease, or cancer. The only clear and consistent difference between the groups was the significantly lower number of dementia diagnoses among those who had access to the shingles shot. "Because of the unique way in which the vaccine was rolled out, bias in the analysis is much less likely than would usually be the case," Dr. Geldsetzer asserted, reinforcing the study’s methodological integrity. Even with this strong initial foundation, the team subjected their data to a variety of alternative analytical approaches. They examined different age windows for comparison and even focused exclusively on deaths where dementia was explicitly listed as a primary cause. Regardless of how the information was "sliced," the consistent and powerful relationship between vaccination and a reduced risk of dementia steadfastly remained. "The signal in our data was so strong, so clear and so persistent," he affirmed. A notable pattern that emerged during the analysis was a difference in outcomes based on sex. The protective effect of the shingles vaccine against dementia appeared to be considerably stronger in women than in men. Dr. Geldsetzer speculated that this disparity might reflect inherent biological differences in immune responses between sexes or variations in how dementia pathologies manifest and progress in men versus women. On average, women tend to mount higher antibody responses following vaccination, and shingles itself occurs more frequently in women than in men. At this juncture, the precise biological mechanisms by which the shingles vaccine might be conferring protection against dementia remain largely unknown. It is not yet clear whether the vaccine functions by broadly stimulating the immune system, by specifically reducing the frequency or severity of varicella-zoster virus reactivation, or through an entirely different biological pathway. Furthermore, it is also unknown whether a newer generation of shingles vaccine, which is a recombinant protein-based vaccine and significantly more effective at preventing shingles than the live-attenuated version used in the Welsh program, would yield a similar or even more pronounced effect on dementia risk. Global Data and the Push for a Randomized Controlled Trial Dr. Geldsetzer expressed his hope that these compelling findings will stimulate greater investment and focus within this vital line of research. "At least investing a subset of our resources into investigating these pathways could lead to breakthroughs in terms of treatment and prevention," he stated, highlighting the potential for transformative discoveries. Over the past two years, his team has extended their investigations, examining health records from other countries that implemented similar shingles vaccine rollout strategies, including England, Australia, New Zealand, and Canada. The results derived from these independent datasets have consistently echoed the protective signal observed in Wales. "We just keep seeing this strong protective signal for dementia in dataset after dataset," he affirmed, providing additional validation for the initial findings. The paramount next step, according to Dr. Geldsetzer, is the initiation of a large-scale randomized controlled trial (RCT). Such a trial would offer the most rigorous and definitive evidence regarding whether the vaccine truly causes the observed reduction in dementia risk, rather than merely being associated with it. In such a study, participants would be randomly assigned to receive either the live-attenuated shingles vaccine or a placebo injection, allowing for a direct comparison of outcomes under controlled conditions. "It would be a very simple, pragmatic trial because we have a one-off intervention that we know is safe," he remarked, emphasizing the feasibility of such an undertaking. Dr. Geldsetzer is actively seeking philanthropic support to fund this critical work, particularly because the live-attenuated vaccine used in the study is now off-patent. While this makes it a cost-effective option for public health, it also means there is less commercial incentive for pharmaceutical companies to fund large-scale trials. He also pointed out that such a trial might yield meaningful results relatively quickly. The data from Wales indicated that when researchers plotted the dementia rates for individuals eligible versus ineligible for the vaccine, the two curves began to diverge noticeably after approximately a year and a half, suggesting that protective effects might become apparent within a reasonable timeframe. The implications of this research are profound. If validated, a widely available and safe vaccine could offer a novel and impactful strategy in the global fight against dementia, shifting the paradigm from solely treating symptoms to actively preventing or significantly delaying the onset of this devastating condition. This work underscores the critical importance of exploring diverse avenues in dementia research and highlights how real-world public health initiatives can inadvertently create invaluable scientific opportunities. A researcher from the Vienna University of Economics and Business also contributed to this significant work. The study received essential funding from several prestigious organizations, including The Phil & Penny Knight Initiative for Brain Resilience, the Stanford Center for Digital Health, the National Institute on Aging (under grant R01AG084535), the National Institute of Allergy and Infectious Diseases (under grant DP2AI171011), and the Biohub, San Francisco. These contributions were crucial in enabling the comprehensive analysis and dissemination of these groundbreaking findings. Post navigation This vaccine uses dental floss instead of needles
